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Several genetic and environmental factors appear to 
cooperate to precipitate type1 diabetes, a 
spontaneous autoimmune disease in humans and in 
the nonobese diabetic (NOD) mouse. NOD mice, 
like type1 diabetic patients, develop insulitis, an 
early infiltration of leukocytes into the pancreas that 
leads to inflammatory lesions within the islets. 
However, overt type1 diabetes requires the 
subsequent destruction of the vast majority of 
insulin producing islet β-cells, a process mediated 
by activation of autoreactive T-helper type1CD4+ 
and subsequently, CD8+ T- cells1. 
 
ROLE OF CHEMOKINES 
T-cells invading pancreatic islets are observed at 
the time of diagnosis of type 1 diabetes. However, 
timing for this invasion (long time or only shortly 
before diagnosis) is unknown. Knowledge about 
this timing is of importance for the planning of 
intervention trials aiming to prevent type 1 diabetes. 
Recently, a new class of small molecules guiding 
cellular migration has been described, the so-called 
chemokines. Chemokines have been divided into 
four subfamilies according to the position of 
cysteine residues: the CXC family with an amino 
acid between two cysteines, the CC family with 
none, the C family with only one cysteine, and the 
CX3C family with three amino acids between two 
cysteines. Chemokines act on their effectors via 
specific receptors that belong to a seven-
transmembrane domain G protein-coupled family. 
These receptors are expressed on leukocytes, 
among them T-cells. Chemokine receptors are 
critically involved in the extravasation of cells into 
inflamed tissue (e.g., the insulitis in type 1 
diabetes). Moreover, the repertoire of chemokine 
receptors is associated with the functional aspects 
of cells. Th1 cells are associated with CCR5 and 
CXCR3 and Th2 cells with CCR3 and CCR4 
chemokine receptors. This finding is intriguing for 
the pathogenesis of type 1 diabetes since this 
disease is likely to be triggered by Th1 
lymphocytes, whereas Th2 lymphocytes may be 
protective. Indeed, in another T-cell-mediated 
autoimmune disease, multiple sclerosis, Th1-
associated chemokine receptors on peripheral blood 
lymphocytes were found to be a marker for immune 
activity of the disease. A striking reduction of the 
Th1-associated chemokine receptors CCR5 and 
CXCR3 on peripheral blood lymphocytes was 
found at the time of diagnosis of type 1 diabetes. 
This finding was reproduced for CD3 and CD4 
cells and correlated with a reduced stimulation of 
the Th1-associated cytokines IFN-γ and TNF-α by 
phytohemagglutinin (PHA). It is assumed that Th1-
associated peripheral T-cells are reduced in a 
narrow time window at the time of diagnosis of 
diabetes, possibly due to extravasation in the 
inflamed pancreas. Thus, chemokine receptor 
expression of peripheral blood lymphocytes may be 
a useful surrogate marker for the immune activity 
of type 1 diabetes (e.g., in intervention trials)2. 
 
ROLE OF CYTOKINES 
An increased expression of cytokines in the insulitis 
has been reported, and different combinations of 
cytokines have been shown to decrease the function 
and viability of β-cells in vitro, partially through the 
production of nitric oxide and/or reactive oxygen 
species by the β-cells themselves or by cells in their 
vicinity, such as macrophages and endothelial cells. 
It has been hypothesized that initial damage to β-
cells could result in the release of intracellular 
components, leading to inflammation and activation 
of a β-cell directed immune response, followed by 
destruction of all insulin-producing cells3. 
 
Interleukin 1 β 
Interleukin (IL)-1β has been proposed as an effector 
in the immune-mediated destruction of pancreatic 
β-cells. Its putative role in the development of type 
1 diabetes is based on in vitro observations 
indicating an IL-1–induced toxicity in isolated 
rodent islets. It is amplified by a simultaneous 
presence of IFN-γ and TNF-α. This combination of 
cytokines is also cytotoxic in human islet 
preparations. IL-1β can kill β-cells by necrosis as 
well as by apoptosis. However, induction of one or 
the other form of cell death depends on the presence 
of additional environmental factors. In vitro 
experiments do not provide information on the 
effectors and mode of β-cell death in type 1 
diabetes. This objective is difficult to achieve with 
in vitro models. Data indicate that if IL-1β is 
released within the islets of the human pancreas, the 




necrosis seen in cultured rat islets. To achieve this 
effect in human islets, local IL-1 levels will have to 
be chronically elevated and lead to toxic 
intercellular nitric oxide (NO) concentrations; this 
will probably require sufficient inducible nitric 
oxide synthase (iNOS) induction in β-cells or 
neighboring non–β-cells as well as a reduced flow 
of the interstitial fluid. If these conditions are not 
met, the cytokine may cause apoptosis of β-cells if 
these are simultaneously and chronically exposed to 
other cytokines such as IFN-γ. Alternatively, IL-1β 
may influence the functional state of the β-cells by 
altering their phenotype and, hence, their responses 




Figure 1: Mechanisms of β- cell destruction (Quoted from Notkins, 200217). 
 
Tumour necrosis factor-α 
Tumor necrosis factor (TNF)- related apoptosis-
inducing ligand (TRAIL) is expressed in different 
tissues and cells, including pancreas and 
lymphocytes, and can induce apoptosis in various 
tumor cells but not in most normal cells. TRAIL 
gene expression is upregulated in pancreatic islets 
during the development of autoimmune type 1 
diabetes in nonobese diabetic (NOD) mice5. 
Studies have suggested that TNF-α expression 
is increased in the pancreatic β cells of NOD mice, 
and this localized TNF-α production plays a critical 
role in both the initiation of insulitis and the 
subsequent progression to β cell destruction. NOD 
mice deficient in TNFR1 receptor develop insulitis 
similar to that of wild-type NOD mice; however, 
progression to diabetes is not observed, indicating 
that β cell toxicity may occur via a TNFR1-
dependent mechanism. Transcriptional inhibition in 
the liver with D-galactosamine increases by several 
thousand-fold the sensitivity of mice to the lethal 
effects of TNF-α. D-galactosamine selectively 
blocks transcription in hepatocytes by depleting 
uridine nucleotides necessary for the production of 
mRNA transcripts. Treatment with TNF-α  in 
conjunction with D-galactosamine results in acute 
liver apoptosis and liver failure. This model of liver 
injury and lethality is mediated by TNF-α signaling 
through the TNFR1 receptor, resulting in activation 
of caspases and subsequent hepatocyte apoptosis6. 
Autoreactive CD4+ T cells play a major role in 
the pathogenesis of autoimmune diabetes in 
nonobese diabetic (NOD) mice. Non-MHC genetic 
background controls enhanced entry into the IFN-γ 
pathway by NOD T cells. Increased IFN-γ, 
decreased IL-4, and decreased IL-10 production in 
NOD T cells is CD4 T cell intrinsic. Therefore, the 
non-MHC NOD genetic background controls the 
cytokine phenotype7.  
Understanding of the final effector phase of 
autoimmune diabetes is becoming an area of intense 
research, due to recent realization of the importance 
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of apoptosis in a variety of physiological or 
pathological conditions. Autoreactive T 
lymphocytes are the most important effector cells in 
autoimmune diabetes, and they ultimately induce 
apoptosis of β islet cells. CD4+ T lymphocytes are 
the final effector cells in β-cell destruction, whereas 
CD8+ T lymphocytes play a role in the initiation 
period of islet destruction. The role of macrophages 
as effector cells has also been suggested. Besides 
their role as APCs, they may also be a source of 
oxygen radicals or other soluble cytotoxic 
mediators. Although effector cells and their roles 
are rather clearly defined, it is far from clear which 
molecule(s) are the real effector(s) in autoimmune 
diabetes.  
A combination of IFN-γ and TNF-α, but neither 
cytokine alone, induced classical caspase-dependent 
apoptosis in insulinoma and pancreatic islet cells. 
IFN-γ treatment conferred susceptibility to TNF-α-
induced apoptosis on otherwise resistant insulinoma 
cells by STAT1 activation followed by IFN 
regulatory factor (IRF)-1 induction. IRF-1 played a 
central role in IFN-γ/TNF-α-induced cytotoxicity 
because inhibition of IRF-1 induction by antisense 
oligonucleotides blocked IFN-γ/TNF-α-induced 
cytotoxicity, and transfection of IRF-1 rendered 
insulinoma cells susceptible to TNF-α-induced 
cytotoxicity. STAT1 and IRF-1 were expressed in 
pancreatic islets of diabetic NOD mice and 
colocalized with apoptotic cells. Moreover, anti-
TNF-α Ab inhibited the development of diabetes 
after adoptive transfer. Taken together, these results 
indicate that IFN-γ/TNF-α synergism is responsible 
for autoimmune diabetes in vivo as well as β-cell 
apoptosis in vitro and suggest a novel signal 
transduction in IFN-γ/TNF-α synergism that may 
have relevance in other autoimmune diseases and 
synergistic anti-tumor effects of the two cytokines8. 
Islet-specific expression of TNF-α can play a 
dual role in autoimmune diabetes, depending on its 
precise timing in relation to the ongoing 
autoimmune process. In a transgenic model (rat 
insulin promoter-lymphocytic choriomeningitis 
virus) of virally induced diabetes, TNF-α enhanced 
disease incidence when induced through an islet-
specific tetracycline-dependent promoter system 
early during pathogenesis. Blockade of TNF-α 
during this phase prevented diabetes completely, 
suggesting its pathogenetic importance early in 
disease development. In contrast, TNF-α expression 
abrogated the autoimmune process when induced 
late, which was associated with a reduction of 
autoreactive CD8 lymphocytes in islets and their 
lytic activities. Thus, the fine-tuned kinetics of an 
autoreactive process undergo distinct stages that 
respond in a differential way to the presence of 
TNF-α. The precise duration of TNF-α expression 
is an important factor determining the progress of 
an ongoing autoimmune process to diabetes. 
However, later during pathogenesis, too much of 
such an inflammatory factor is not beneficial to the 
propagation of the autoimmune process. This could 
occur in vivo, for example, by a second infection by 
the same or another unrelated virus capable of 
inducing inflammatory factors. Indeed, such a 
scenario has been observed in rat insulin promoter-
lymphocytic choriomeningitis virus (RIP-LCMV) 
model, in which secondary viral infection can 
abrogate ongoing autoimmunity by enhancing 
apoptosis of autoreactive lymphocytes. 
Furthermore, TNF-α was demonstrated in various 
other occasions to confer immunoregulatory 
activities by down-regulation of type 1 cytokines, 
suppression of T cell proliferation and cytokine 
production, or preventing the development of self-
reactive T lymphocytes9. 
 
BREAKDOWN OF SELF-TOLERANCE 
There is mounting evidence that CD4+CD25+ T 
cells represent an important mechanism for the 
maintenance of self-tolerance. CD4+CD25+ T cells 
prevent experimentally induced organ-specific 
autoimmune disease. Removal of these cells from 
mice that normally do not develop autoimmune 
disease can result in autoimmunity. The effects of 
TNF in disease, are often contradictory and 
puzzling. Elevation of TNF levels during the 
neonatal period in NOD mice intensifies the 
diabetic process, while injection of neutralizing 
anti-TNF into newborn NOD mice resulted in 
complete prevention of disease. Interestingly, if 
TNF treatment was started in the adult NOD mouse, 
disease onset was delayed, and the incidence of 
diabetes was decreased or abrogated. Anti-TNF 
administered during the young adult period did not 
yield complete protection from diabetes and may 
even accelerate the diabetic process. NOD mice 
have a relative deficiency of CD4+CD25+ T cells 
in thymus and spleen and administration of TNF or 
anti-TNF to NOD mice can modulate levels of this 
population consistent with their observed 
differential age-dependent effects on diabetes in the 
NOD mouse. These data suggest that alterations in 
the number and function of CD4+CD25+ T cells 
may be one mechanism by which TNF and anti-
TNF modulate type I diabetes mellitus in NOD 
mice10. 
In the periphery, activation of self-reactive 
CD8+ T cells usually involves cross-presentation of 
exogenous self-antigen by antigen presenting cells 
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(APCs) bearing MHC self-peptides. Such cross-
presentation normally induces expansion followed 
by deletion of self-reactive CD8+ T cells. 
Breakdown in tolerization of self-reactive CD8+ T 
cells can lead to autoimmunity. It is unclear what 
governs whether APCs promote expansion and 
survival of activated self-reactive CD8+ T cells or 
their expansion followed by deletion. Inflammatory 
cytokines have been implicated in the breakdown of 
tolerance to self-antigens11.  
 
ANTIGEN PRESENTING CELLS 
The differentiation of naive CD8+ T cells into 
effector cytotoxic T lymphocytes (CTLs) normally 
requires the interaction of three types of cells: 
APCs bearing peptide–MHC complexes, CD4+ T 
cells, and CD8+ T cells. CD4+ T cell help the 
differentiation of naive CD8+ T cells into effector 
CTLs is at the level of the APC, where initial 
engagement of CD4+ T cells with APCs triggers the 
maturation of the APC into a cell fully competent to 
prime CD8+ T cells. Interactions between CD40 on 
APCs and CD154 on activated CD4+ T cells play a 
dominant role in the generation of T and B cell 
immunity. Several autoimmune conditions have 
been shown to be dependent on CD40–CD154 
signals, and in diabetes, blockade of CD40–CD154 
signals abrogates both insulitis and diabetes. TNF-α 
enhances autoimmunity in NOD mice by provoking 
islet-infiltrating APCs to cross-present exogenous 
islet antigen to CD8+ T cells. Effector CD4+ T cells 
are not required for the priming of islet-specific 
CD8+ T cells. TNF-α can substitute for CD4+ T cell 
help in the cross-presentation of exogenous islet 
antigen to CD8+ T cells by overcoming the need for 
CD154 signals in the activation of islet-infiltrating 
APCs. These findings reveal that inflammatory 
stimuli may promote autoimmunity by thwarting 
normal CD4+ T cell–dependent CD154 immune 
regulatory mechanisms11. 
 
NATURAL KILLER T LYMPHOCYTES 
Extensive work in the early 90s established the 
importance of the Th1/Th2 paradigm and showed 
that Th2 CD4+ lymphocytes can dampen Th1-
mediated immune responses. Later experiments 
highlighted the importance of a new subset of 
lymphocytes, termed NKT cells, in the regulation of 
Th2 cell differentiation. These NKT cells are 
distinct from other thymus-derived lymphocytes in 
that they express some markers typical of NK cells, 
as well as a quasi-invariant T cell receptor (TCR) 
type. Following stimulation of this TCR, NKT cells 
produce large amounts of IL-4, which drives the 
differentiation and growth of Th2 cells. This 
finding suggested that NKT cells could directly 
control physiological Th2-driven immune responses 
and thus indirectly regulate Th1-mediated 
autoimmunity.  
Because NKT cells are abundant in the liver 
and bone marrow but are present in very small 
numbers in peripheral lymphoid organs, this 
hypothesis was initially controversial, but it soon 
received strong support from experiments 
performed in genetically manipulated mice. In 
particular, work with mice lacking the β2 
microglobulin chain, which are NKT cell-deficient 
because they lack the MHC class I-restricting 
element CD1d, indicated that NKT cells are indeed 
important players in Th2 differentiation and IgE 
production. Moreover, Vα14Jα281 transgenic mice, 
which harbour a large population of NKT cells, 
show heightened Th2 polarization and high serum 
levels of IgE. Data showed a major deficiency of 
NKT cell numbers in nonobese diabetic (NOD) 
mice, a well-established model of spontaneous, 
autoimmune T-cell mediated insulin-dependent 
diabetes. Both the number of NOD NKT cells and 
the functional capacity of these cells, as assessed by 
IL-4 release following TCR ligation, are 
dramatically reduced. Moreover, in vivo treatment 
with the specific NKT cell TCR ligand α-galactosyl 
ceramide (α-GalCer, a glycolipid derived from a 
marine sponge) prevents disease in NOD mice. 
Over-expression of NKT cell-associated 
Vα14Jα281 TCR chain in transgenic mice has a 
similar effect. Conversely, the onset of diabetes was 
reported to be accelerated in NOD mice lacking 
CD1d expression, consistent with a pathogenic role 
for NKT cell deficiency. Unfortunately, such 
studies in human patients are intrinsically limited 
by the poor representation of NKT cells among 
circulating mononuclear cells12. 
In their report, Lee et al (2002)13 have 
characterized NKT cells using double staining with 
a CD1d–α-GalCer tetramer and a Vα24 specific 
antibody. They found that the numbers of NKT 
cells did not differ between diabetic patients, 
subjects at high risk for developing the disease, and 
normal controls. IL-4 production by NKT cells was 
also similar among these groups, as assessed by 
intracytoplasmic staining following short-term 
phorbol myristate acetate (PMA) and ionomycin 
stimulation. These observations are in clear 
distinction with previous reports showing both a 
numerical and a functional defect in the IL-4 
producing ability of NKT cells in diabetic patients, 
as compared to both discordant twins and normal 
controls.  
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The discrepancies between these studies are 
difficult to explain, since the methods for detecting 
NKT cells and the functional assays employed 
differ significantly. While the use of CD1d 
tetramers in Lee et al13 report adds considerably to 
the specificity of detection, this protocol may also 
identify low avidity tetramer-binding cells whose 
biological relevance is questionable. Moreover, the 
assumption that α-GalCer binds to all NKT cells 
may be incorrect in light of some reports showing 
that there are invariant and non-invariant CD1d-
restricted T cells that do not respond to this 
glycolipid. Hence, the double-staining procedure 
applied may have missed some NKT cells. 
Conversely, since α-GalCer loaded CD1d tetramers 
have been reported to stain CD1d-restricted T cells 
not expressing the invariant Vα24 TCR chain, it is 
also possible that some of the cells identified by this 
procedure are not NKT cells. Finally, because Lee’s 
group examined whole mononuclear cells that had 
been triggered with PMA and ionomycin, it is not 
possible to compare their data with those of earlier 
reports, where clones of NKT cells were expanded 
in culture and stimulated in a more physiological 
manner via the TCR12. 
 
PROTECTIVE CYTOKINES 
The mechanism underlying suppression of immune 
responses by interleukin-4 (IL-4) has remained 
unexplained. Antigen-presenting dendritic cell (DC) 
is central to counter-regulation of autoimmune 
disease by IL-4. Stimulation of cytotoxic precursors 
by antigen pulsed dendritic cells induces their 
differentiation but the process is blocked by IL-4. 
IL-4-influenced DC to produce distinct effects on 
CD8+ T cells depending on their state of activation. 
The molecular basis for this regulation is the 
alteration of the expression ratio of the 
costimulatory ligands B7.1/B7.2 on dendritic cells. 
B7.2 induces expansion of CD8+ T cells and B7.1 
governs their acquisition of cytolytic activity. IL-4 
influences the dendritic cell to elicit qualitative 
differences in T-cell responses, providing the basis 
for the counter-regulation mediated by IL-414. 
Using the biodegradable polymer, poly[alpha-
(4-aminobutyl)-L-glycolic acid] (PAGA), 
interleukin-4 (IL-4) plasmid (pCAGGS-IL-4), was 
injected intravenously at the age of 4 weeks to 
prevent autoimmune insulitis in NOD mice. At 6 
weeks after the injection, the grade of insulitis of 
the mice was evaluated by double blind methods. In 
vitro transfection assays showed that PAGA 
enhanced the expression of IL-4 in 293T cells. In 
the plasmid/PAGA complex injected group, the 
prevalence of severe insulitis in NOD mice was 
markedly improved, suggesting that PAGA 
enhanced the delivery of IL-4 plasmid. The 
pCAGGS-IL-4/PAGA complex is thus an effective 
system to prevent autoimmune insulitis in NOD 
mice and is applicable for the prevention of 
autoimmune diabetes15. 
Several findings have recently questioned the 
long held hypothesis that cytokines belonging to the 
Th2 pathway are protective in T-cell-mediated 
autoimmunity. It was found that pancreatic 
expression of IL-4 activated islet antigen-specific 
BDC2.5 T cells and rendered them able to trigger 
insulin-dependent diabetes mellitus in ins-IL-
4/BDC2.5 mice. IL-4 is mainly known as the Th2-
driving cytokine. However, IL-4 is also critical for 
DC maturation and upregulation of antigen uptake 
and presentation by macrophages. Pancreatic 
expression of IL-4 activated self-reactive BDC2.5 T 
cells by increasing islet antigen presentation by 
macrophages and dendritic cells. Therefore, IL-4 
could have triggered self-antigen presentation 
within the pancreatic islets both by driving 
maturation of DC from a tolerizing to a priming 
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